


1fw



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of **Janina Baranowski-Kortylewicz, et al.**
Application No. 10/671,376
Attorney Docket No. 0685-UNMC.63184
Filing Date: September 25, 2003
For: **CANCER SPECIFIC RADIOLABELED CONJUGATES
REGULATED BY THE CELL CYCLE FOR THE
TREATMENT AND DIAGNOSIS OF CANCER**
Examiner: Not Yet Assigned
Group Art Unit: 1632

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)

I hereby certify that this Correspondence is being deposited on June 8, 2004 with the United States Postal Service as first-class mail in an envelope properly addressed to COMMISSIONER FOR PATENTS, P.O. Box 1450, Alexandria, VA 22313-1450.

June 8, 2004
Date of Certificate

Patrick J. Hagan
Patrick J. Hagan

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97**

In compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicants are submitting herewith a Form PTO-1449 and a copy of the references listed thereon. This Information Disclosure Statement is being filed prior to the mailing of a first Official Action on the merits. Accordingly, no fee is required.

In the opinion of the undersigned, the references submitted herewith are the most pertinent of which the undersigned is aware. However, no representation is made or intended that more pertinent references do not exist.

This submission is not an admission that the references listed on the attached Form PTO-1449 constitute prior art against the claims of this application.

The Examiner is respectfully requested to confirm receipt and consideration of the cited references by initialing and returning a copy of the attached Form PTO-1449 in accordance with MPEP §609.

Early and favorable consideration of this application is respectfully requested.

Respectfully submitted,

DANN, DORFMAN, HERRELL & SKILLMAN
A Professional Corporation
Attorneys for Applicant(s)

By Patrick J. Hagan
Patrick J. Hagan
PTO Registration No. 27,643


Telephone: (215) 563-4100

Facsimile: (215) 563-4044

Enclosures - Form PTO-1449

Copies of references listed on PTO - 1449

INFORMATION DISCLOSURE STATEMENT



Complete if known

Application Number: 10/671,376
 Filing Date: September 25, 2003
 First Named Inventor: Janina Baranowska-Kortylewicz, et al.
 Group Art Unit: 1632
 Examiner Name: Not Yet Assigned
 Attorney Docket Number: 0685-UNMC.63184

SHEET 1 OF 2

UNITED STATES PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
	A1	5,096,694	03/17/1992	Quivy et al.
	A2	5,468,853	11/21/1993	Baranowska-Kortylewicz

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT
	B1	WO 90/03799	WO	04-19-1990	Centocor, Inc.


OTHER PRIOR ART - NON-PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C1	BONASERA, T.A. et al. "Preclinical Evaluation of Fluorine-18-Labeled Androgen Receptor Ligands in Baboons"; Journal of Nuclear Medicine, 37(6) : 1009-1015 (1996)
	C2	CHOE, Y.S. et al. "Synthesis of 11 β -[¹⁸ F]Fluro-5 α -dihydrotestosterone and 11 β -[¹⁸ F]Fluro-19-nor-5 α -dihydrotestosterone: Preparation via Halofluorination-Reduction, Receptor Binding, and Tissue Distribution"; Journal of Medicinal Chemistry, 38(5) : 816-825 (1995)
	C3	DOWNER, J.B. et al. "Comparison of animal models for the evaluation of radiolabeled androgens"; Nuclear Medicine and Biology, 28(6) : 613-626 (2001)
	C4	HOYTE, R.M. et al. "7 α -Methyl-17 α -(E-2'-[¹²⁵ I]iodovinyl)-19-nortestosterone: a new radioligand for the detection of androgen receptor"; Steroids, 58(1) : 13-23 (1993)
	C5	LABAREE, D.C. et al. "7 α -Iodine-125-Iodo-5 α -Dihydrotestosterone: A Radiolabeled Ligand for the Androgen Receptor"; Journal of Nuclear Medicine, 38(3) : 402-409 (1997)
	C6	LARA, P.N. et al. "Treatment Options in Androgen-Independent Prostate Cancer"; Cancer Investigation, 17(2) : 137-144 (1999)
	C7	LIU, A. et al. "Fluorine-18-Labeled Androgens: Radiochemical Synthesis and Tissue Distribution Studies on Six Fluorine-Substituted Androgens, Potential Imaging Agents for Prostatic Cancer"; Journal of Nuclear Medicine, 33(5) : 724-734 (1992)
	C8	SALMAN, M. et al. "A Potential Radioiodinated Ligand for Androgen Receptor: 7 α -Methyl-17 α -(2'-(E)-iodovinyl)-19-nortestosterone"; Journal of Medicinal Chemistry, 34(3) : 1019-1024 (1991)

EXAMINER'S SIGNATURE	DATE CONSIDERED
----------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT



Complete if known

Application Number: 10/671,376
 Filing Date: September 25, 2003
 First Named Inventor: Janina Baranowska-Kortylewicz, et al.
 Group Art Unit: 1632
 Examiner Name: Not Yet Assigned
 Attorney Docket Number: 0685-UNMC.63184

SHEET 2 OF 2

C9	VAN DEN BOS, J.C., et al. "New Iodinated Progestins as Potential Ligands for Progesterone Receptor Imaging in Breast Cancer. Part 1: Synthesis and <i>in Vitro</i> Pharmacological Characterization"; Nuclear Medicine & Biology, 25(8) : 781-789 (1998)
C10	WARTERS, R.L. et al. "Radionuclide Toxicity in Cultured Mammalian Cells: Elucidation of the Primary Site of Radiation Damage"; Current Topics in Radiation Research Quarterly, 12 : 389-407 (1997)
C11	MAKRIGIORGOS, G.M. et al. "Radiotoxicity of 5-[¹²³ I]Iodo-2'-deoxyuridine in V79 Cells: A Comparison with 5-[¹²⁵ I]Iodo-2'-deoxyuridine"; Radiation Research, 118 : 532 (1989)
C12	BARANOWSKA-KORTYLEWICZ, J. et al. "5-[¹²³ I]Iodo-2'-Deoxyuridine in the Radiotherapy of an Early Ascites Tumor Model"; Int. J. Radiat. Oncol. Biol. Phys., 21 : 1541-1551 (1991)
C13	KYRIAKOS, R.J. et al. "The Fate of Antibodies Bound to the Surface of Tumor Cells <i>in Vitro</i> "; Cancer Research, 52 : 835-842 (1992)
C14	BRYAN, R.M. et al. "Androgen Receptors in Breast Cancer"; Cancer, 54 : 2436-2440 (1984)
C15	LEA, O.A. et al. "Improved Measurement of Androgen Receptors in Human Breast Cancer"; Cancer Research, 49 : 7162-7167 (1989)
C16	SOREIDE, J.A. et al. "Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment"; European Journal of Surgical Oncology, 18 : 112-118 (1992)
C17	POULIN, R. et al. "Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line"; Breast Cancer Research and Treatment, 12 : 213-225 (1988)
C18	INGLE, J.N. et al. "Combination Hormonal Therapy With Tamoxifen Plus Fluoxymesterone Versus Tamoxifen Alone in Postmenopausal Women With Metastatic Breast Cancer"; Cancer, 67 : 886-891 (1991)
C19	MARIANI, G. et al. "Tumor Targeting Potential and Metabolism of 5-[¹²⁵ I]Iodo-2'-Deoxyuridine Injected Intratumorally in Patients with Breast Cancer"; Ann N Y Acad. Sci., 698 : 204-211 (1993)

EXAMINER'S SIGNATURE		DATE CONSIDERED	
-------------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.